Stockreport

Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease

Axon Enterprise, Inc.  (AXON) 
Last axon enterprise, inc. earnings: 2/7 04:15 pm Check Earnings Report
US:NYSE Investor Relations: investors.axovant.com/investors/sec-filings
PDF ~ Conference call for analysts to be held at 2:30pm BST / 9:30am ET (see details below) OXFORD, England--(BUSINESS WIRE)-- Oxford BioMedica pl [Read more]